LONDON, STAINES, England and SAN FRANCISCO, March 30, 2011 (ots/PRNewswire) — Astellas Pharma Europe Ltd. and Medivation, Inc. today announced treatment of the first patient in the TERRAIN trial, a Phase 2 comparison of the investigational drug MDV3100, a triple-acting, oral androgen receptor antagonist, with bicalutamide, a commonly used non-steroidal anti-androgen, for the treatment of [...]
Tag Archive > Prostate Cancer
R&D Productivity Measures Consistently Under-Scored and Under-Valued, EvaluatePharma Data Reveals
London (ots/PRNewswire) – Pharmaceutical R&D productivity is consistently undercounted. Most reports fail to fully count the number of new drugs that reach the market, missing out on billions of dollars of sales generated by R&D investment, an analysis of EvaluatePharma data shows. Most counts of FDA new drug approvals in 2010 failed to include likely [...]
Medivation and Astellas Complete Enrollment in Phase 3 AFFIRM trial of MDV3100 in Advanced Prostate Cancer
San Francisco and Tokyo, November 30 (ots/PRNewswire) – Medivation, Inc. and Astellas Pharma Inc. today announced that patient enrollment was completed on November 15, 2010 in the Phase 3 AFFIRM study of the investigational drug MDV3100, a novel, triple-acting oral androgen receptor antagonist, in patients with advanced prostate cancer who have previously been treated with [...]
EANS-News: Epigenomics and Predictive Biosciences Extend Licensing Deal for Prostate Cancer Test
——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Licensing Agreements/Company Information/Molecular diagnostics BERLIN, PHILADELPHIA, PA and LEXINGTON, MA, November 16, 2010 (euro adhoc) – Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer diagnostics company, and Predictive Biosciences, a commercial stage, fully-integrated developer of novel [...]
Dendreon gibt Termine für Präsentationen im Rahmen des 35. Kongresses der Europäischen Gesellschaft für medizinische Onkologie bekannt
Seattle und Mailand (ots/PRNewswire) – Dendreon Corporation hat heute die folgenden Termine für Präsentationen im Rahmen des 35. Kongresses der europäischen Gesellschaft für medizinische Onkologie (ESMO) in Mailand, Italien bekannt gegeben: – Samstag, 9.Oktober 2010, 13:00 – 14:00 MESZ – “Integrated Safety Results from 4 Randomized, Double-blind, Placebo-controlled Studies of Sipuleucel-T. (Integrierte Resultate aus 4 [...]
Prolia(R) (Denosumab) Granted Marketing Authorization in the European Union
Thousand Oaks, California, May 28, 2010 (ots/PRNewswire) – Amgen Inc. today announced that the European Commission (EC) has granted marketing authorization for Prolia(R) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased [...]
Bei der Behandlung des Prostatakrebses sollte der Mann als Ganzes
Barcelona, Spanien, April 21, 2010 (ots/PRNewswire) – Medizinische Fachkräfte sollten die Auswirkungen des Prostatakrebses auf den Mann als Ganzes berücksichtigen, statt den Schwerpunkt nur auf die isolierte Behandlung des Krebses zu legen, so die Ergebnisse einer internationalen Umfrage bei Prostatakrebspatienten und ihren Partnern. Um die Multimedia Pressemitteilung anzuzeigen, klicken Sie bitte hier: http://multivu.prnewswire.com/mnr/prne/ferring/42412/ Die Ergebnisse [...]
Amgen Receives CHMP Positive Opinion for Prolia(TM) (Denosumab) in the European Union
Thousand Oaks, California (ots/PRNewswire) – Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia(TM) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of [...]
Auftrieb für Prostatakrebsvorsorge – Bericht belegt Verringerung der Sterblichkeit um bis zu 31 %
Rotterdam, Niederlande (ots/PRNewswire) – – Eine individuelle “Risikoabschätzung” verringert unnötige Biopsien um 33 %, so die jüngsten Ergebnisse der ERSPC-Studie Die Effizienz des PSA-Tests (Prostata-spezifisches Antigen) zur Verringerung der Sterblichkeit durch Prostatakrebs erhielt durch neue Ergebnisse der ERSPC-Studie (European Randomized Study of Screening for Prostate Cancer) weiteren Auftrieb. Sie ergab, dass die tatsächlichen Auswirkungen viel [...]
Men, Partners and Patients in Europe United Against Prostate Cancer
Barcelona, Spain (ots/PRNewswire) – – New Survey Highlights Need for Education Resources, Critical Role of Physician in Patient Communication and Importance of Maintaining Normal Lifestyle During Treatment Findings from a survey of European prostate cancer patients, presented at the 2nd European Multidisciplinary Meeting on Urological Cancers (EMUC) in Barcelona, Spain, highlight the need for further [...]
Eckert & Ziegler verleiht Reisepreis an nuklearmedizinische Nachwuchsforscher
Berlin (ots) – Die diesjährigen Reisepreise der Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE 0005659700) sind an fünf Nuklearmediziner aus Deutschland, Italien, Polen und der Schweiz verliehen worden. Die Preisträger wurden von einer Jury der European Association of Nuclear Medicine (EANM) unter insgesamt 520 Einsendungen ausgewählt. Ausgezeichnet wurden Arbeiten auf den Gebieten der [...]
Astellas Pharma Europe gibt die Gewinner der Changing Tomorrow 2009 Awards bekannt
Staines, England (ots/PRNewswire) – Astellas Pharma Europe Ltd., das europäische Tochterunternehmen der Astellas Pharma Inc. mit Sitz in Tokio und eines der zwanzig weltweit grössten Pharmaunternehmen, gab heute den Start von Astellas Changing Tomorrow Charity Awards bekannt. Die Charity Award Förderung soll Organisationen auszeichnen, die Bürgern aller Gemeinschaften dabei helfen, ihr volles Potential zu realisieren [...]
Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 – ESMO 34 Congress
Thousand Oaks, California (ots/PRNewswire) – – Key Denosumab and Vectibix(R) (Panitumumab) Data to be Presented Amgen (Nasdaq: AMGN) today announced it will present detailed data from four Phase 3 studies as well as other data at the ECCO 15 – ESMO 34 European Multidisciplinary Congress, September 20 – 24, 2009 in Berlin, Germany. Researchers will [...]
EANS-News: Epigenomics AG Certified for Diagnostic Product Development and Commercialization
ISO 13485 certification marks a milestone in Epigenomics’ commercial strategy ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– companies/new product/Molecular Diagnostics Press release, Berlin, Germany, and Seattle, WA, USA, June 30, 2009 (euro adhoc) – Epigenomics AG (Frankfurt Prime Standard: ECX), a molecular diagnostics [...]
Eckert & Ziegler’s associated company IBt Bebig signs contracts about a joint venture in the Russian Federation
(pressebox) Berlin, 23.06.2009, Belgian International Brachytherapy S.A. (IBt Bebig), an associated company of Eckert & Ziegler AG (ISIN DE0005659700), the Russian State Fund Corporation Rusnanotech Corp. and the marketing company Santis Ltd. agreed on the construction of a new production site in the Russian Federation. "NanoBrachyTech", holding a minority share of 15% at IBt Bebig, [...]
